search
Back to results

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Indacaterol maleate
Indacaterol maleate
Indacaterol maleate
Placebo
Sponsored by
Novartis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All Sexes

Inclusion Criteria:

  • Male and female patients 18 to 65 years old (inclusive)
  • Patients with mild to moderate persistent asthma
  • BMI must be within the range of 18-32 kg/m2 inclusive
  • Female subjects must:

    1. have been sterilized at least 6 months prior to screening
    2. be post-menopausal with no regular bleeding for at least a year prior to inclusion

Exclusion Criteria:

  • Patients with life-threatening arrhythmias
  • Patients with COPD or diabetes mellitus
  • History of immunocompromise, including a positive HIV
  • A positive Hepatitis B surface antigen (HBsAg) of Hepatitis C test result

Other protocol-defined inclusion/exclusion criteria may apply.

Sites / Locations

  • Novartis Investigator Site
  • Novartis Investigator Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

Active Comparator 1 different salt formulation of Indacaterol.

Active Comparator 2 different salt formulation of Indacaterol.

Active Comparator 3 different salt formulation of Indacaterol.

Outcomes

Primary Outcome Measures

Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Severity of cough: to be judged independently by both the patient and the physician
Occurrence of cough within 1 minute post dose
Number of coughs
Duration of coughing

Secondary Outcome Measures

Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Severity of cough: to be judged independently by both the patient and the physician
Occurrence of cough within 1 minute post dose
Number of coughs
Duration of coughing

Full Information

First Posted
February 15, 2008
Last Updated
December 16, 2020
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00624702
Brief Title
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
Official Title
A Multi-center, Randomized, Single-dose, Double-blind, 4-way Cross-over Study to Evaluate Tolerability Following Treatment With Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
98 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Active Comparator 1 different salt formulation of Indacaterol.
Arm Title
2
Arm Type
Active Comparator
Arm Description
Active Comparator 2 different salt formulation of Indacaterol.
Arm Title
3
Arm Type
Active Comparator
Arm Description
Active Comparator 3 different salt formulation of Indacaterol.
Arm Title
4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Time Frame
throughout the study
Title
Severity of cough: to be judged independently by both the patient and the physician
Time Frame
throughout the study
Title
Occurrence of cough within 1 minute post dose
Time Frame
throughout the study
Title
Number of coughs
Time Frame
throughout the study
Title
Duration of coughing
Time Frame
throughout the study
Secondary Outcome Measure Information:
Title
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Time Frame
throughout the study
Title
Severity of cough: to be judged independently by both the patient and the physician
Time Frame
throughout the study
Title
Occurrence of cough within 1 minute post dose
Time Frame
throughout the study
Title
Number of coughs
Time Frame
throughout the study
Title
Duration of coughing
Time Frame
throughout the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Inclusion Criteria: Male and female patients 18 to 65 years old (inclusive) Patients with mild to moderate persistent asthma BMI must be within the range of 18-32 kg/m2 inclusive Female subjects must: have been sterilized at least 6 months prior to screening be post-menopausal with no regular bleeding for at least a year prior to inclusion Exclusion Criteria: Patients with life-threatening arrhythmias Patients with COPD or diabetes mellitus History of immunocompromise, including a positive HIV A positive Hepatitis B surface antigen (HBsAg) of Hepatitis C test result Other protocol-defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Novartis investigator site
Official's Role
Principal Investigator
Facility Information:
Facility Name
Novartis Investigator Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
Novartis Investigator Site
City
Montreal
State/Province
Quebec
Country
Canada

12. IPD Sharing Statement

Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3022
Description
Results for QAB149B2102 can be found on the Novartis Clinical Trial Results Website

Learn more about this trial

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

We'll reach out to this number within 24 hrs